SCHEMBL1144600

SCHEMBL1144600

COc1ccc2c(C(=O)N3CCN(C(=O)OC(C)(C)C)CC3)c(Cl)n(-c3ccccc3)c2c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HPGD P15428 1/20 0.51
REN P00797 3/20 0.47
MAPK8 P45983 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
GPR119 Q8TDV5 1/20 0.42
SLC2A1 P11166 1/20 0.42
USP14 P54578 1/20 0.42
STS P08842 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144092 0.92 ALDH1A1 (0.61) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1144657 0.91 REN (0.48) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1144687 0.89 REN (0.53) ALDH1A1KMT2AMEN1RENMAPK8
SCHEMBL1144661 0.87 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1144191 0.87 CHRM2 (0.52) KMT2AMEN1RENPOLBGPR119
SCHEMBL1149661 0.84 REN (0.49) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1144332 0.83 REN (0.65) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1150369 0.82 REN (0.49) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1149890 0.82 REN (0.49) ALDH1A1KMT2AMEN1KDM4EHPGD
SCHEMBL1149614 0.82 REN (0.50) KMT2AMEN1RENPOLBGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247575-B1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2016-03-23 EP disclosed
US-8211885-B2 Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-07-03 US disclosed
US-20110039830-A1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-02-17 US disclosed
EP-2247575-A2 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2010-11-10 EP disclosed
WO-2009095163-A2 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039830-A1 CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS REN, ACE, PM20D2 ALDH1A1 2427/4885KMT2A 2044/4885MEN1 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.